Table of Contents
Advances in Hepatology
Volume 2014 (2014), Article ID 493087, 13 pages
http://dx.doi.org/10.1155/2014/493087
Review Article

Ribavirin at the Era of Novel Direct Antiviral Agents for the Treatment of Hepatitis C Virus Infection: Relevance of Pharmacological Monitoring

1Department of Hepatology, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, 103 grande rue de la Croix-Rousse, 69004 Lyon, France
2INSERM U1052, 69003 Lyon, France
3Université Lyon I, Lyon, France
4Ecole Normale Supérieure, 69007 Lyon, France
5Department of Pharmacology, Hôpital Edouard Herriot, Hospices Civils de Lyon, 69003 Lyon, France
6Institut Universitaire de France, Paris, France

Received 2 June 2014; Revised 29 August 2014; Accepted 11 September 2014; Published 30 September 2014

Academic Editor: Jun Yong Park

Copyright © 2014 Pierre Pradat et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Pierre Pradat, Victor Virlogeux, Marie-Claude Gagnieu, Fabien Zoulim, and François Bailly, “Ribavirin at the Era of Novel Direct Antiviral Agents for the Treatment of Hepatitis C Virus Infection: Relevance of Pharmacological Monitoring,” Advances in Hepatology, vol. 2014, Article ID 493087, 13 pages, 2014. doi:10.1155/2014/493087